Search results for "Meropenem"

showing 10 items of 17 documents

Determination of meropenem in endotracheal tubes by in-tube solid phase microextraction coupled to capillary liquid chromatography with diode array d…

2017

Meropenem is a widely used antimicrobial for the treatment of infections associated with the use of invasive medical devices in intensive care unit patients. These treatments are not always effective, in fact, in-vitro studies have demonstrated the difficulty of antimicrobials to penetrate into the biofilm, however in-vivo studies of the effect of these compounds is a trend, mostly because of the complexity of pulmonary samples extracted from ETTs. Therefore, the objective of this study was to evaluate in-tube solid phase microextraction (in-tube SPME) coupled to capillary liquid chromatography (CapLC) with DAD to determine meropenem in Errs in order to estimate the penetration capability i…

0301 basic medicineCapillary action030106 microbiologyClinical BiochemistryPharmaceutical ScienceEndotracheal tubesengineering.materialSolid-phase microextraction01 natural sciencesMeropenemAnalytical Chemistry03 medical and health sciencesCapillary columnCoatingCapillary ElectrochromatographyLimit of DetectionCapillary-LC-DADDrug DiscoverymedicineIntubation IntratrachealHumansSpectroscopySolid Phase MicroextractionChromatographyChemistryBiofilm010401 analytical chemistryIn-tube SPMEPenetration (firestop)MeropenemDiode array0104 chemical sciencesAnti-Bacterial AgentsCapillary lengthengineeringThienamycinsmedicine.drugChromatography LiquidJournal of pharmaceutical and biomedical analysis
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants.

2015

Abstract Introduction Extended-spectrum beta-lactamase (ESBL) producing bacteria are infrequent pathogens of urinary tract infections in children. The objective of our study was to investigate the presence, clinically associated characteristics and risk factors for acquisition of urinary tract infection/acute pyelonephritis (UTI/APN) in hospitalised children Methods A case-control study in a second level community hospital in Spain, in which 537 episodes of UTI/APN were investigated in a retrospective study between November 2005 and August 2014. Cases were patients with ESBL strains. For each case, four ESBL-negative controls were selected. A questionnaire with the variables of interest was…

0301 basic medicineMalemedicine.medical_specialtyFevermedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsHospitals CommunityComorbidityFosfomycinTazobactamVesicoureteral refluxMeropenembeta-Lactam Resistancebeta-Lactamases03 medical and health sciencesBacterial ProteinsRisk FactorsInternal medicineSurveys and Questionnairespolycyclic compoundsmedicineEscherichia coliHumansEscherichia coli InfectionsRetrospective StudiesVesico-Ureteral RefluxInpatientsPyelonephritisbusiness.industryInfantbiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaseSurgeryCommunity-Acquired InfectionsSpainCase-Control StudiesUrinary Tract InfectionsBeta-lactamasebacteriaGentamicinFemalebusinessmedicine.drugPiperacillinEnfermedades infecciosas y microbiologia clinica
researchProduct

Enterococcal meningitis caused by Enterococcus casseliflavus. First case report

2005

Abstract Background Enterococcal meningitis is an uncommon disease usually caused by Enterococcus faecalis and Enterococcus faecium and is associated with a high mortality rate. Enterococcus casseliflavus has been implicated in a wide variety of infections in humans, but never in meningitis. Case presentation A 77-year-old Italian female presented for evaluation of fever, stupor, diarrhea and vomiting of 3 days duration. There was no history of head injury nor of previous surgical procedures. She had been suffering from rheumatoid arthritis for 30 years, for which she was being treated with steroids and methotrexate. On admission, she was febrile, alert but not oriented to time and place. H…

BACTEREMIACase ReportMicrobial Sensitivity TestsVANCOMYCIN-RESISTANT ENTEROCOCCI; CLINICAL-FEATURES; BACTEREMIA; GALLINARUM; MOTILE ENTEROCOCCUS; OUTCOMESMeropenemEnterococcus faecalisVANCOMYCIN-RESISTANT ENTEROCOCCIlcsh:Infectious and parasitic diseaseslaw.inventionMicrobiologyMeningitis BacteriallawAmpicillinmedicineEnterococcus casseliflavusHumanslcsh:RC109-216Gram-Positive Bacterial InfectionsAgedCerebrospinal FluidOUTCOMESSigmoid Diseasesbiologybusiness.industryCLINICAL-FEATURESMeropenembiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsMOTILE ENTEROCOCCUSInfectious DiseasesGram stainingEnterococcusSulbactamGALLINARUMAmpicillinFemaleThienamycinsbusinessMeningitisEnterococcusmedicine.drugEnterococcus faeciumBMC Infectious Diseases
researchProduct

In silico identification and experimental validation of hits active against KPC-2 β-lactamase

2018

Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type β-lactamases are often reported as resistant to available β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, …

Genetics and Molecular Biology (all)Proteomics0301 basic medicineCefotaximeKlebsiella pneumoniaePathology and Laboratory MedicinePhysical ChemistryBiochemistryKlebsiella PneumoniaeDatabase and Informatics MethodsBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)AntibioticsKlebsiellaCatalytic DomainMedicine and Health Sciencespolycyclic compoundsDrug InteractionsCrystallographyMultidisciplinarybiologyAntimicrobialsOrganic CompoundsProteomic DatabasesChemistryPhysicsQRDrugsSulbactamCondensed Matter PhysicsBacterial PathogensChemistryBiochemistryMedical MicrobiologyPhysical SciencesCrystal StructureMedicinePathogensbeta-Lactamase InhibitorsResearch Articlemedicine.drugScienceIn silico030106 microbiologySulfonamideResearch and Analysis MethodsMicrobiologyMeropenemTazobactambeta-Lactamases03 medical and health sciencesBacterial ProteinsMicrobial ControlClavulanic acidmedicineSolid State PhysicsMicrobial PathogensPharmacologyLigand efficiencyChemical BondingBacteriaOrganic ChemistryChemical CompoundsOrganismsBiology and Life SciencesHydrogen Bondingbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesAmidesBiological Databases030104 developmental biologyAgricultural and Biological Sciences (all)
researchProduct

Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy

2012

Abstract Background Multidrug-resistant Acinetobacter baumannii, initially considered as having a poor clinical relevance, is frequently isolated from infection cases in intensive care units. We describe the epidemiology of carbapenem resistant A. baumannii (CRAB) in a general ICU in Palermo, Italy, from October 2010 to March 2011. Findings 58 of 61 isolates exhibited MICs for meropenem or imipenem ≥16 mg/L. Forty-nine carried blaOXA-23 and two blaOXA-58 genes. Five subtype clusters were detected by rep-PCR. Clusters D and E included 10 isolates that tested negative for the carbapenem resistance genes. MLST attributed all isolates, but two, with sequence type (ST)2, whereas the two remainin…

MaleAcinetobacter baumanniiImipenemSettore MED/07 - Microbiologia E Microbiologia ClinicaTime Factorslcsh:MedicineTigecyclinePolymerase Chain Reactionintensive care unitlaw.inventionlawDrug Resistance Multiple BacterialEpidemiologypolycyclic compoundsMedicinelcsh:QH301-705.5Medicine(all)Aged 80 and overbiologyGeneral MedicineMiddle AgedIntensive care unitAcinetobacter baumanniiIntensive Care UnitsItalyFemaleAcinetobacter baumannii; intensive care unitAcinetobacter Infectionsmedicine.drugAdultmedicine.medical_specialtyAdolescentShort ReportMicrobial Sensitivity TestsMeropenemGeneral Biochemistry Genetics and Molecular BiologyYoung AdultIntensive careHumansIntensive care medicinelcsh:Science (General)AgedDemographyBiochemistry Genetics and Molecular Biology(all)business.industrylcsh:Rbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationClone CellsCarbapenemslcsh:Biology (General)bacteriabusinessCarbapenem resistant Acinetobacter baumanniilcsh:Q1-390BMC Research Notes
researchProduct

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

2014

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether α-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 α-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f TMIC) an…

MaleInternational CooperationAntibioticsadverse eventintensive care unitlaw.invention0302 clinical medicinemeropenemModels[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illnessantibiotic therapyProspective Studiesamoxicillin plus clavulanic acidComputingMilieux_MISCELLANEOUSbeta lactam antibioticAPACHE0303 health sciencescritical illneadultclinical trial3. Good healthcontinuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.antiinfective agent[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journaldisease severitybeta-Lactamstatistical model Agedprospective studyHumanMicrobiology (medical)medicine.medical_specialtydrug exposureCritical IllnessImmunologybloodstream infectionMicrobial Sensitivity Testspiperacillin plus tazobactambeta-LactamsMicrobiologybeta lactam abdominal infection03 medical and health sciencescritically ill patientIntensive careAnti-Bacterial AgentcefepimepharmacodynamicsHumansDosingAdverse effectAgedModels Statistical030306 microbiologyOdds ratiomajor clinical studymortalityantibiotic sensitivityceftriaxoneProspective Studiemulticenter studypharmacodynamics.ampicillinBlood Chemical AnalysisCeftazidimeSettore MED/41 - AnestesiologiaInterquartile rangelaw030212 general & internal medicinepharmacokineticlung infectionMicrobial Sensitivity TestarticleBacterial InfectionsMiddle AgedStatisticalcontinuous infusionIntensive care unitAnti-Bacterial Agentsextended infusionIntensive Care UnitsInfectious DiseasesTreatment Outcomeadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illness; Microbiology (medical); Infectious Diseasescefazolin[SDV.IMM]Life Sciences [q-bio]/Immunologyblood samplingFemalepharmacokineticsmedicine.drugmedicine.drug_classprevalencedoripenemminimum inhibitory concentrationBacterial InfectionInternal medicinemedicinecontrolled studyblood analysibusiness.industryBlood Chemical Analysiadverse eventsSurgerypharmacodynamicdrug blood levelbusiness
researchProduct

Parietal subdural empyema as complication of acute odontogenic sinusitis: a case report

2014

Introduction: To date intracranial complication caused by tooth extractions are extremely rare. In particular parietal subdural empyema of odontogenic origin has not been described. A literature review is presented here to emphasize the extreme rarity of this clinical entity. Case presentation: An 18-year-old Caucasian man with a history of dental extraction developed dysarthria, lethargy, purulent rhinorrhea, and fever. A computed tomography scan demonstrated extensive sinusitis involving maxillary sinus, anterior ethmoid and frontal sinus on the left side and a subdural fluid collection in the temporal-parietal site on the same side. He underwent vancomycin, metronidazole and meropenem th…

Malemedicine.medical_specialtyAdolescentMaxillary sinusmedicine.medical_treatmentCase ReportSubdural empyemaSubdural SpaceDiagnosis DifferentialIntracranial infections Odontogenic sinusitis Paranasal sinusitis Subdural empyemaVancomycinMetronidazoleParietal LobemedicineHumansSinusitisSubdural spaceSinusitisCraniotomyOdontogenic sinusitisSubdural empyemaMedicine(all)Empyema SubduralFrontal sinusrhinorrheabusiness.industryParanasal sinusitisSettore MED/37 - NeuroradiologiaSequelaMeropenemGeneral MedicineMaxillary Sinusmedicine.diseaseAnti-Bacterial AgentsSurgerySettore MED/32 - AudiologiaTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaIntracranial infectionsAcute DiseaseTooth ExtractionThienamycinsmedicine.symptomTomography X-Ray ComputedbusinessCraniotomyFollow-Up Studies
researchProduct

New β-Lactam-β-Lactamase Inhibitor Combinations.

2020

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, an…

Microbiology (medical)DrugImipenemBacilliEpidemiologyKlebsiella pneumoniaemedia_common.quotation_subjectMicrobial Sensitivity Testsmedicine.disease_causebeta-LactamsMeropenemMicrobiologyDrug Resistance Multiple BacterialGram-Negative Bacteriapolycyclic compoundsmedicinemedia_commonGeneral Immunology and MicrobiologybiologyPseudomonas aeruginosabusiness.industryPublic Health Environmental and Occupational Healthbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationCeftazidime/avibactamAcinetobacter baumanniiDrug CombinationsInfectious DiseasesbacteriaErratumbusinessbeta-Lactamase Inhibitorsmedicine.drugClinical microbiology reviews
researchProduct

Multiclonal emergence of carbapenem-resistant Klebsiella pneumoniae in Tuscany, Italy

2010

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaImipenemGenotypemedicine.drug_classCarbapenem resistant Klebsiella pneumoniaemedicine.medical_treatmentAntibioticsMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E ApplicataMeropenembeta-Lactam Resistancebeta-LactamasesMicrobiologychemistry.chemical_compoundmedicineHumansPharmacology (medical)Molecular EpidemiologyKlebsiella pneumoniae resistenza ai carbapenemi multiclonaleGeneral MedicineDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaePhenotypeInfectious DiseasesCarbapenemsItalychemistryBeta-lactamaseErtapenemmedicine.drugBeta lactam antibioticsInternational Journal of Antimicrobial Agents
researchProduct